NDA Deficiencies Prolonged Review Of Lunesta Sleep Aid – FDA

Inadequacies in Sepracor's NDA for the insomnia drug Lunesta (eszopiclone) kept FDA from reaching an approval decision during the first review cycle, agency review documents indicate